|
|
Volumn 515, Issue 7526, 2014, Pages 177-178
|
|
Ethical dilemma for Ebola drug trials
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMIODARONE;
ANTIBODY;
ANTIINFECTIVE AGENT;
EBOLA VACCINE;
ANTISERUM;
VIRUS ANTIBODY;
ANALGESIA;
BLOOD ANALYSIS;
CLINICAL EFFECTIVENESS;
CLINICAL RESEARCH;
CLINICAL TRIAL (TOPIC);
CONVALESCENCE;
DRUG BIOAVAILABILITY;
DRUG SCREENING;
EBOLA HEMORRHAGIC FEVER;
EBOLA VIRUS;
EPIDEMIC;
EXPERIMENTAL THERAPY;
FAMILY ASSESSMENT;
FEAR;
FLUID THERAPY;
FOOD AND DRUG ADMINISTRATION;
GUINEA;
HEALTH CARE PERSONNEL;
HEALTH CARE PLANNING;
HEALTH CARE QUALITY;
HUMAN;
INTERVENTION STUDY;
MEDICAL ETHICS;
MORTALITY;
NATIONAL HEALTH ORGANIZATION;
NONHUMAN;
NOTE;
PALLIATIVE THERAPY;
PATIENT CARE;
PRIORITY JOURNAL;
PUBLIC HEALTH;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SECONDARY INFECTION;
TROPICAL DISEASE;
VIOLENCE;
VIROTHERAPY;
WORLD HEALTH ORGANIZATION;
AFRICA;
BLOOD GROUP TYPING;
COMPASSIONATE USE;
CONTROLLED CLINICAL TRIAL (TOPIC);
EPIDEMIOLOGY;
ETHICS;
EVIDENCE BASED MEDICINE;
HEMORRHAGIC FEVER, EBOLA;
IMMUNOLOGY;
PASSIVE IMMUNIZATION;
STANDARDS;
TREATMENT OUTCOME;
UNITED STATES;
AFRICA, WESTERN;
ANTIBODIES, VIRAL;
BLOOD GROUPING AND CROSSMATCHING;
COMPASSIONATE USE TRIALS;
CONTROLLED CLINICAL TRIALS AS TOPIC;
EBOLAVIRUS;
EVIDENCE-BASED MEDICINE;
HEMORRHAGIC FEVER, EBOLA;
HUMANS;
IMMUNE SERA;
IMMUNIZATION, PASSIVE;
NATIONAL INSTITUTES OF HEALTH (U.S.);
PUBLIC HEALTH;
TREATMENT OUTCOME;
UNITED STATES;
WORLD HEALTH ORGANIZATION;
|
|
EID: 84922042292
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/515177a Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|